Vicarious Surgical Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephen From
- Full Time Employees
- 123
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 78 Fourth Avenue Waltham MA United States of America 02451
- IPO Date
- Sep 4, 2020
- CIK
- 0001812173
- Website
- vicarioussurgical.com
- Similar Companies
- Business
- Vicarious Surgical Inc. (NYSE: RBOT) develops next-generation robotics technology for minimally invasive surgery, focusing on abdominal procedures through a single port. The company offers the Vicarious Surgical System, comprising a patient cart, surgeon console, miniaturized robotic arms with 28 sensors per arm for human-like motion and force feedback, and an immersive 3D high-definition stereoscopic camera providing 360-degree visualization and depth mapping; this system enables incisions of approximately 1.5 centimeters, full nine degrees of freedom per arm, and access to nearly every abdominal surface while replicating surgeons' natural upper body movements. Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical targets hospitals and surgical centers in the United States, with plans for broader commercialization pending FDA approval, which it has received Breakthrough Device Designation for its robot. Recent developments include a reduction in full-year 2025 cash burn guidance to $45 million from $50 million through operational efficiencies and cost management under CEO Stephen From, who assumed leadership in 2025; outsourcing of non-core functions such as capital equipment and certain software following investor feedback and a restructuring with headcount reductions; a $5.9 million registered direct offering in October 2025 to bolster its balance sheet; and plans to achieve design freeze for the production-equivalent system by late 2026 while prioritizing clinical trial preparation.
Vicarious Surgical Demonstrates Sustained System Performance and Complex Hernia Procedure Workflows in Pre-Clinical Setting
Vicarious Surgical Reports First Quarter 2026 Financial Results
Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair
Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing
Head-To-Head Survey: Waters (NYSE:WAT) vs. Vicarious Surgical (NYSE:RBOT)
Vicarious Surgical Announces Strategic Plan to Pursue Nasdaq Listing
Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results
Vicarious Surgical Receives Delisting Notice From NYSE
NYSE to Commence Delisting Proceedings Against Vicarious Surgical Inc. (RBOT)
Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab
RBOT Enters Strategic Software Partnership to Streamline Development
Vicarious Surgical Announces Strategic Software Execution Partnership to Streamline Operations
NYSE to Commence Delisting Proceedings with Respect to Warrants of Vicarious Surgical Inc. (RBOT WS)
Vicarious Surgical Announces Full Year 2026 Cash Burn Guidance
Vicarious Surgical Announces Reduction in 2025 Cash Burn Outlook
Vicarious Surgical to Participate in the Piper Sandler 37th Annual Healthcare Conference
Vicarious Surgical Inc. (RBOT) Q3 2025 Earnings Call Transcript
Vicarious Surgical Reports Third Quarter 2025 Financial Results
Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 12, 2025
Vicarious Surgical Announces Pricing of $5.9 Million Registered Direct Offering